GlycoEra develops biologic therapeutics that selectively degrade pathogenic circulating proteins, such as autoantibody IgG4, to treat autoimmune diseases. Its platform enables rapid, deep, and specific removal of disease‑driving extracellular targets while preserving overall immune function. This precision immunology approach aims to allow earlier intervention, improve patient outcomes, and reduce reliance on broad immunosuppression.
Funding
$63.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMFounders
Product
Problem
Existing therapies for autoimmune diseases often broadly suppress the immune system, leading to an increased risk of infection and other side effects. These treatments are typically used as late-line interventions, after the disease has progressed, limiting their effectiveness and impact on patient quality of life.
Solution
GlycoEra is developing a new class of biologics for precision immunology, designed to selectively degrade specific circulating proteins, such as autoantibodies, that drive autoimmune diseases. Their platform enables rapid, selective, and deep removal of target proteins while avoiding broad immunosuppression. This approach allows for earlier intervention in the disease process, potentially improving patient outcomes, reducing long-term complications, and lowering overall healthcare costs. GlycoEra's lead program, GE8820, is designed to degrade pathogenic IgG4 autoantibodies with a speed, depth and high level of selectivity not attainable with current modalities and without immunosuppression.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases and the healthcare providers who treat them, specifically those seeking more targeted and effective therapies with fewer side effects.
Features
- Biologics engineered for selective degradation of specific circulating proteins.
- Target extracellular proteins, such as autoantibodies in autoimmune disease or protein aggregates in neurological disease.
- Platform applicable to multiple distinct targets, demonstrating reproducibility across diseases driven by circulating proteins.
- Potential for improved safety profile compared to broad-spectrum immunosuppressants.
- Designed for early intervention to improve patient quality of life and limit long-term complications.